Background: The mode of action of corticosteroids, important drugs in
the treatment of inflammatory disease, is not yet fully understood. Co
rticosteroids are known to inhibit phospholipase A(2) in unprimed eosi
nophils and basophils, preventing leukotriene synthesis, but their eff
ect on cells that are already primed is unknown. Objective: As inflamm
atory cells from atopic subjects are often primed in vivo, we studied
the effects of two potent corticosteroids on basophil sulfidoleukotrie
ne production in peripheral blood mixed leukocytes (PBML) from in-seas
on and out-of-season atopic individuals. Methods: Cells were incubated
for 24 hours with mometasone furoate or beclomethasone dipropionate,
primed with IL-3, stimulated with calcium ionophore, buffer, allergen
or anti-IgE, and leukotriene production was quantified. Results: Perip
heral blood mononuclear leukocytes from five of ten donors (in season)
produced elevated sulfidoleukotrienes without a stimulus; cells from
seven donors responded to anti-IgE by increased sulfidoleukotrienes. N
either steroid consistently affected sulfidoleukotriene production in
anti-IgE-stimulated cells which were releasing sulfidoleukotrienes in
the absence of a stimulant. In comparison, sulfidoleukotriene producti
on was significantly reduced by 0.01 to 10 nM beclomethasone dipropion
ate or mometasone furoate when the cells were primed with IL-3 after e
xposure to the drug and stimulated with calcium ionophore or allergen,
but no dose-relationship was apparent. Leukotriene production by PBML
in response to anti-IgE was potently inhibited by all concentrations
of mometasone furoate (0.01 nM to 1 mu M) with an inhibitory concentra
tion,, of less than 0.01 nM. Beclomethasone dipropionate inhibited sul
fidoleukotriene production in this group (inhibitory concentration(50)
6 nM) in a dose-dependent manner. Conclusions: Sulfidoleukotriene pro
duction and, conceivably, priming may be more effectively inhibited by
mometasone furoate than beclomethasone dipropionate.